Amgen Delivers Q2 Results with Revenue Growth
Earnings Beat Estimates, Revenue Surpasses Expectations
Amgen (NASDAQ: AMGN) has released its financial results for the second quarter ended June 30, 2024. The company reported quarterly earnings of 497 per share, exceeding the Zacks Consensus Estimate. Revenue for the quarter reached 8.39 billion, a year-over-year increase.
Q2 Highlights
Amgen's total revenues grew 6% year-over-year to 8.39 billion in Q2 2024. The company reported adjusted earnings of 497 per share, narrowly missing the analyst estimate of 500 per share. Key products, including Prolia, Xgeva, and Enbrel, drove revenue growth.
For the full year, Amgen provided guidance excluding any contribution from its announced acquisition. The company expects total revenues to range between 8.2 billion and 8.6 billion.
Continued Growth and Innovation
Amgen remains committed to scientific research and development. The company has a robust pipeline of innovative therapies, including several late-stage candidates. These therapies have the potential to address unmet medical needs and drive future growth.
Overall, Amgen's Q2 results demonstrate the company's strong financial performance and its focus on innovation. The company's continued investment in R&D is expected to drive long-term growth and value creation for shareholders.
Comments